At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Synergistic Pharmacologic Intervention for Prevention of ROP (SPIPROP STUDY)
In Brief
A Phase 2 clinical trial evaluating Caffeine citrate, Ibuprofen, and 1 other intervention for Retinopathy of Prematurity. Completed, enrolled 14 participants across 1 site.
Detailed Summary
Phase 2, open-label, randomized, multi-center studies in infants and premature infants are necessary to determine treatment and preventative strategies for ROP. This study was designed to: a) target infants at the highest risk of ROP in a large number of centers with variable rates of ROP (all stages and severe ROP or stage 3+); and b) assess whether caffeine plus systemic or ophthalmic NSAID will decrease ROP among infants most at risk for ROP. The study is designed to determine whether the novel treatment regimens are safe and potentially effective for ROP prevention and to obtain requisite data for the development of a Phase III efficacy/safety randomized blinded trial. Since caffeine is used extensively in NICUs as standard of care for ELGANs, no placebo group is included.
Study Details
Timeline
Interventions
Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose)
Ibuprofen (10 mg/kg loading dose followed by low dose ibuprofen 2.5 mg/kg/day) for 5 days
Ketorolac (Acuvail) eye drops (one drop two times a day) for 14 days